<DOC>
	<DOCNO>NCT01993875</DOCNO>
	<brief_summary>To evaluate pharmacodynamics tolerability liquid formulation lubiprostone , compare match placebo , administer orally subject chronic idiopathic constipation . Additionally , liquid formulation pharmacokinetics , include comparison fed fast pharmacokinetics , liquid formulation perform subset subject .</brief_summary>
	<brief_title>Pharmacodynamic , Pharmacokinetic , Tolerability Study Liquid Form Lubiprostone Adult Subjects With Chronic Idiopathic Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>Medicallyconfirmed diagnosis chronic idiopathic constipation Willing discontinue use prescribe overthecounter ( OTC ) medication affect gastrointestinal motility study Stable dose selective serotonin reuptake inhibitor ( SSRIs ) , serotoninspecific reuptake inhibitor ( SNRIs ) , monoamine oxidase inhibitor ( MAO ) inhibitors Any gastrointestinal ( GI ) condition , constipation , affect GI motility defecation . Medical/surgical condition might interfere absorption , distribution , metabolism , excretion study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>